Infectious Disease Therapeutics Market is expected to reach US$ 1,67,883.93 million by 2030

Anti-viral Segment to Hold Significant Share of Infectious Disease Therapeutics Market During 2022–2030  

According to our latest study on "Infectious Disease Therapeutics Market Forecast to 2030 – Global Analysis – by Drug Class, Indication, Route of Administration, and Distribution Channel," the infectious disease therapeutics market size was valued at US$ 1,19,708.77 million in 2022 and is expected to reach US$ 1,67,883.93 million by 2030. The market is estimated to register a CAGR of 4.3% from 2022 to 2030. The rising prevalence of infectious diseases and increasing focus on funding and R&D in infectious disease therapeutics are the key driving factors behind the market development. However, the emergence of anti-infective drug resistance and associated side effects impede the infectious disease therapeutics market growth.

The infectious disease therapeutics market forecast predicts significant growth in coming years, owing to advancements in medical research and growing demand for advanced therapeutics.

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0–14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) ranks 13th in the leading causes of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe drives the infectious disease therapeutics market size.

Infectious Disease Therapeutics Market, by Drug Class:

The infectious disease therapeutics market forecast involves the segmentation of the market based on drug class, indication, route of administration, and distribution channel. The infectious disease therapeutics market analysis estimated that the anti-viral segment held the largest share of the market in 2022; the anti-bacterial segment is likely to register the highest CAGR in the infectious disease therapeutics market during 2022–2030. Anti-viral agents are drugs approved by the US Food and Drug Administration (FDA) for treating viral infections. Anti-viral agents typically target distinct phases of the viral life cycle. Anti-viral medications can be used for prevention, treatment, suppression, or overt disease. Several strategies are used to develop anti-viral agents, including direct-acting anti-viral targeting enzymes, viral proteins, or nucleic acids; passive antibodies neutralizing circulating viruses; and drugs targeting cellular proteins or processes essential for viral replication. Half of the currently offered anti-viral agents are used for the purpose of treating human immunodeficiency virus (HIV) infections. The other drugs are primarily used to treat herpes viruses, hepatitis B, hepatitis C, and respiratory viruses. For instance, as per the WHO statistics, in 2019, there were 690,000 deaths due to HIV globally, recording 1.7 million new cases of HIV infection, with overall cases of ~38 million.

The infectious disease therapeutics market analysis, by route of administration has been carried out by considering the following segments: oral, parenteral, topical, and others. The oral segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the infectious disease therapeutics market during 2022-2030.

Infectious Disease Therapeutics Market, by Indication:

The infectious disease therapeutics market, by indication, is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. In 2022, in terms of revenue, HIV dominated the global infectious disease therapeutics market share and is anticipated to register the highest CAGR in the market during 2022–2030. HIV weakens an individual’s immune system by destroying important cells that fight disease and infection. Due to various factors, including sexual partners and risky behaviors, some groups of people in the US are more likely to contract HIV than others. The risk of getting an infection after surgery can rise due to growing immune system suppression by HIV. The number of patients with HIV infection has been steadily rising in recent years. The life expectancy of HIV infection and AIDS patients has significantly increased since the introduction of antiretroviral therapy (ART). Thus, with the continuous rise in the need for surgical care and the prevalence of surgical diseases that result from HIV infection, the market for infectious disease therapeutics is expected to grow during the forecast period.

Infectious Disease Therapeutics Market, by Geography:

Based on geography, the infectious disease therapeutics market is primarily divided into North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).  In 2022, in terms of revenue, North America dominated the global infectious disease therapeutics market share. Asia Pacific is expected to register the highest CAGR during 2022–2030. Factors such as rising healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base propel the infectious disease therapeutics market growth in the region.

The infectious disease therapeutics market forecast is estimated based on various secondary and primary research findings such as key company publications, associations data, and databases. The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Joint United Nations Programme on HIV/AIDS (UNAIDS), National AIDS Trust are among the major primary and secondary sources referred to while preparing the global infectious disease therapeutics market report.

Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Shionogi & Co Ltd, Bayer AG, BioCryst Pharmaceuticals Inc, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc are the prominent players profiled in infectious disease therapeutics market report.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com